ID27398A - Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida - Google Patents

Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida

Info

Publication number
ID27398A
ID27398A IDW20002515A ID20002515A ID27398A ID 27398 A ID27398 A ID 27398A ID W20002515 A IDW20002515 A ID W20002515A ID 20002515 A ID20002515 A ID 20002515A ID 27398 A ID27398 A ID 27398A
Authority
ID
Indonesia
Prior art keywords
stabilization
composition containing
magnesium oxide
ace inhibitors
containing ace
Prior art date
Application number
IDW20002515A
Other languages
English (en)
Indonesian (id)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokason
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID27398A publication Critical patent/ID27398A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20002515A 1998-06-05 1999-05-10 Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida ID27398A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
ID27398A true ID27398A (id) 2001-04-05

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002515A ID27398A (id) 1998-06-05 1999-05-10 Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida

Country Status (32)

Country Link
US (3) US6417196B1 (https=)
EP (1) EP1083931B1 (https=)
JP (1) JP3727848B2 (https=)
KR (1) KR20010052557A (https=)
CN (1) CN1144598C (https=)
AR (1) AR019150A1 (https=)
AT (1) ATE295184T1 (https=)
AU (1) AU755616B2 (https=)
BR (1) BR9910947A (https=)
CA (1) CA2330581A1 (https=)
CO (1) CO5011043A1 (https=)
DE (1) DE69925269T2 (https=)
ES (1) ES2242398T3 (https=)
GT (1) GT199900079A (https=)
HK (1) HK1038879B (https=)
HN (1) HN1999000088A (https=)
HU (1) HUP0102260A3 (https=)
ID (1) ID27398A (https=)
IL (1) IL139590A0 (https=)
IS (1) IS2270B (https=)
MY (1) MY119667A (https=)
NO (1) NO20006148D0 (https=)
NZ (1) NZ508544A (https=)
PA (1) PA8475001A1 (https=)
PE (1) PE20000543A1 (https=)
PL (1) PL344586A1 (https=)
SV (1) SV1999000072A (https=)
TR (1) TR200003600T2 (https=)
TW (1) TW565455B (https=)
UY (1) UY25546A1 (https=)
WO (1) WO1999062560A1 (https=)
ZA (1) ZA200006537B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2408796C (en) * 2000-05-24 2009-12-15 Otsuka Pharmaceutical Co., Ltd. Method of stabilizing preparation
UA78542C2 (en) * 2002-01-15 2007-04-10 Actavis Group Hf Formulations of quinapril and other ace inhibitors
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
WO2005002548A1 (en) * 2003-06-26 2005-01-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
CA2653382A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) 1967-05-16 Method of preparing magnesia
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
DE69925269D1 (de) 2005-06-16
TW565455B (en) 2003-12-11
CO5011043A1 (es) 2001-02-28
IS2270B (is) 2007-07-15
AU755616B2 (en) 2002-12-19
CN1304322A (zh) 2001-07-18
KR20010052557A (ko) 2001-06-25
US7015232B2 (en) 2006-03-21
HN1999000088A (es) 2000-02-10
ES2242398T3 (es) 2005-11-01
HUP0102260A3 (en) 2002-12-28
NO20006148L (no) 2000-12-04
UY25546A1 (es) 1999-09-27
PE20000543A1 (es) 2000-08-10
JP3727848B2 (ja) 2005-12-21
ATE295184T1 (de) 2005-05-15
EP1083931A1 (en) 2001-03-21
ZA200006537B (en) 2001-11-12
EP1083931B1 (en) 2005-05-11
CN1144598C (zh) 2004-04-07
IL139590A0 (en) 2002-02-10
GT199900079A (es) 2000-11-25
NO20006148D0 (no) 2000-12-04
SV1999000072A (es) 2000-05-04
NZ508544A (en) 2002-10-25
US20020161020A1 (en) 2002-10-31
IS5712A (is) 2000-11-10
HK1038879B (zh) 2004-10-08
HK1038879A1 (en) 2002-04-04
WO1999062560A1 (en) 1999-12-09
US20060106057A1 (en) 2006-05-18
US6417196B1 (en) 2002-07-09
JP2002516881A (ja) 2002-06-11
MY119667A (en) 2005-06-30
HUP0102260A2 (hu) 2002-03-28
BR9910947A (pt) 2001-03-06
DE69925269T2 (de) 2006-02-23
CA2330581A1 (en) 1999-12-09
PL344586A1 (en) 2001-11-05
TR200003600T2 (tr) 2001-04-20
AU3979399A (en) 1999-12-20
PA8475001A1 (es) 2000-09-29
AR019150A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
ID27398A (id) Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida
AU2524902A (en) Use of MoO<sub>3</sub> as corrosion inhibitor, and coating composition containing such an inhibitor
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
AU2002357137A8 (en) (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
AU8969601A (en) New use of lipase inhibitors
FI941766L (fi) sPLA2:n 1H-indoli-3-etikkahappohydratsidi-inhibiittoreita
NO20035635D0 (no) Substituerte naftylindol-derivater som inhibitorer av plasminogen-aktivatorinhibitor type-1 (PAI-1)
PT2270005E (pt) Pró-fármaco de um inibidor de ice
PL350228A1 (en) Dimeric compounds and as inhibitors of neuraminidase
IL137718A0 (en) Inhibitors of phospholipase enzymes
DE60106968D1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
HUP0302068A3 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
PL369312A1 (en) Novel compounds and compositions as cathepsin inhibitors
GB2348199B (en) Corrosion inhibitor compositions and methods of making them
IL150806A0 (en) Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
EP1085872A4 (en) TRANSCRIPTION FACTOR NF- $ g (k) B INHIBITORS
PL343678A1 (en) Pyrrolidines as inhibitors of neuraminidases
DE60108495D1 (en) Thrombin inhibitoren
IL161476A (en) Phosphonic acid compounds as inhibitors of serine proteases
GB2337518B (en) Dissolution inhibitor of chemically amplified photoresist and chemically amplified photoresist composition containing the same
AU2153897A (en) Mixtures of reducing-action sulphur compounds and organic corrosion inhibitors and their use as corrosion-inhibiting bleaching or reducing agents
DE60012208D1 (de) Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs
AU1212002A (en) Use of lipase inhibitors
PL355625A1 (en) Use of formulations for treating surfaces for temporarily improving dirt-removing behavior
WO2004089354A3 (en) Peptides and derivatives thereof as inhibitors of oxidative-induced degradation phenomena and compositions containing them